Combination of S100B and procalcitonin improves prognostic performance compared to either alone in patients with cardiac arrest

Abstract

This study aimed to determine whether the combination of procalcitonin (PCT) and S100B improves prognostic performance compared to either alone in cardiac arrest (CA) patients treated with targeted temperature management (TTM). We performed a prospective cohort study of CA patients treated with TTM. PCT and S100B levels were obtained at 0, 24, 48, and 72 hours after return of spontaneous circulation. The prognostic performance was analyzed using each marker and the combination of the 2 markers for predicting poor neurological outcome at 3 months and mortality at 14 days and 3 months. A total of 97 patients were enrolled, of which 67 (69.1%) had poor neurological outcome. S100B showed a better prognostic performance (area under the curve [AUC], 0.934; sensitivity, 77.6%; and specificity, 100%) than PCT (AUC, 0.861; sensitivity, 70.2%; and specificity, 83.3%) with the highest prognostic value at 24 hours. The combination of 24-hour PCT and S100B values (S100B ≥0.2 μg/L or PCT ≥6.6 ng/mL) improved sensitivity (85.07%) compared with S100B alone. In multivariate analysis, PCT was associated with mortality at 14 days (odds ratio [OR]: 1.064, 95% confidence interval [CI]: 1.014–1.118), whereas S100B was associated with neurological outcomes at 3 months (OR: 9.849, 95% CI: 2.089–46.431). The combination of PCT and S100B improved prognostic performance compared to the use of either biomarker alone in CA patient treated with TTM. Further studies that will identify the optimal cutoff values for these biomarkers must be conducted.

Prediction of poor neurological outcome in comatose survivors of cardiac arrest: a systematic review

“…Target temperature varied across studies (ESM Table E3). Fifteen studies [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] were included for clinical examination, 12 for biomarkers [37][38][39][40][41][42][43][44][45][46][47][48], 26 for electrophysiology , and 15 for imaging [75][76][77][78][79][80][81][82][83][84][85][86][87][88][89], while 26 studies were included for more than one prognostic modality.…”

“…Sensitivity and FPR for index tests based on clinical examination, biomarkers, electrophysiology, and imaging are reported in Tables 3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,…”

“…In four studies [37,39,42,44], high blood values of S-100B protein predicted poor outcome with 0% FPR from immediately after ROSC to 72 h after ROSC. The relevant threshold values varied widely (Table 15).…”

Adult Advanced Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations

“…The accuracy of S-100B protein in predicting poor outcome in patients with ROSC after cardiac arrest was investigated in 3 observational studies. 251 , 253 , 254 …”

“…In 2 studies, 251 , 254 S-100B protein with threshold ranging from 3.58 to 16.6 μg/L immediately after ROSC predicted poor neurological outcome from 3 to 6 months with 100% specificity and sensitivity ranging from 2.8% to 26.9% (certainty of evidence from moderate to very low).…”